Loading...
Market
First region to approve BLINCYTO® for pediatric B-cell ALL post-ASH24 by end of 2025?
2
Resolution / Starting Odds
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
Official health regulatory announcements from respective regions
Story
Amgen's BLINCYTO® Improves Survival in Pediatric B-Cell ALL: AALL1731 Results at ASH24
Dec 8, 2024, 02:04 PM
At the American Society of Hematology's (ASH) 2024 Annual Meeting (#ASH24), significant clinical trial results were presented, highlighting advancements in the treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL). A key study presented by the Children's Oncology Group (COG) revealed that the addition of blinatumomab, marketed as BLINCYTO® by Amgen, to induction chemotherapy significantly improved disease-free survival in children with standard-risk B-ALL. The full results of the AALL1731 trial demonstrated enhanced survival rates when blinatumomab was added to chemotherapy regimens for newly diagnosed pediatric patients with B-cell precursor acute lymphoblastic leukemia.
View original story
Similar markets
United States • 25%
United Kingdom • 25%
Canada • 25%
Other • 25%
Canada • 25%
European Union • 25%
Japan • 25%
Other • 25%
Europe • 25%
Asia • 25%
South America • 25%
Other • 25%
Europe • 25%
Asia • 25%
North America • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
European Union • 25%
Canada • 25%
Japan • 25%
Other • 25%
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
European Union • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Europe • 25%
Asia • 25%
South America • 25%
Africa • 25%